BDTX - NASDAQ
Black Diamond Therapeutics, Inc.
$2.10
-7.1%Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotBlack Diamond Therapeutics, Inc. Management Team
Ms. Melanie Morrison
Chief Development Officer
Dr. Mark A. Velleca M.D., Ph.D.
Chief Executive Officer, President & Chairman
Compensation
$972,842
Dr. Sergey Yurasov M.D., Ph.D.
Chief Medical Officer
Compensation
$725,969
Mr. Brent Hatzis-Schoch Esq., J.D.
Chief Operating Officer & General Counsel
Compensation
$703,735
Dr. Elizabeth Buck Ph.D.
Co-Founder & Chief Scientific Officer
Compensation
$340,473
Ms. Erika Jones
Principal Financial Officer, Principal Accounting Officer, SVice President of Finance & Corporate Controller
Black Diamond Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $500K worth of BDTX shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
8.1K
27.25K
0
0.00
+27K
+$27K
9-12 Months
195.0K
472.67K
0
0.00
+473K
+$473K
Top Buyers
Behbahani Ali
Director
$103K
Raman Prakash
Director
$100K
Campbell Shannon
Director
$74K
Dhingra Kapil
Director
$74K
Kulkarni Samarth
Director
$74K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $500K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
BDTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 18, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 24, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2023 | May 16, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 07, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 18, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.